New York State Teachers Retirement System Sells 30,822 Shares of Abbott Laboratories $ABT

New York State Teachers Retirement System decreased its holdings in Abbott Laboratories (NYSE:ABT) by 2.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,489,044 shares of the healthcare product maker’s stock after selling 30,822 shares during the period. New York State Teachers Retirement System’s holdings in Abbott Laboratories were worth $186,562,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Harbor Capital Advisors Inc. bought a new position in Abbott Laboratories in the fourth quarter worth approximately $27,000. Cloud Capital Management LLC bought a new position in Abbott Laboratories in the third quarter worth approximately $29,000. Guerra Advisors Inc bought a new position in Abbott Laboratories in the third quarter worth approximately $31,000. Bridge Generations Wealth Management LLC bought a new position in Abbott Laboratories in the third quarter worth approximately $33,000. Finally, Copia Wealth Management bought a new position in Abbott Laboratories in the third quarter worth approximately $38,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 0.9%

NYSE ABT traded down $0.81 on Thursday, hitting $90.52. The stock had a trading volume of 2,710,772 shares, compared to its average volume of 11,480,752. The business’s fifty day moving average price is $104.76 and its 200 day moving average price is $116.38. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a 52-week low of $90.29 and a 52-week high of $139.06. The stock has a market cap of $157.66 billion, a price-to-earnings ratio of 25.39, a price-to-earnings-growth ratio of 1.55 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. The firm had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. During the same period in the previous year, the company earned $1.09 earnings per share. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ABT. Sanford C. Bernstein reduced their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Citigroup cut their price target on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Benchmark cut their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Mizuho cut their price target on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Finally, Wells Fargo & Company cut their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $119.43.

Insider Buying and Selling at Abbott Laboratories

In related news, VP John A. Jr. Mccoy sold 585 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the transaction, the vice president owned 24,628 shares in the company, valued at $2,846,504.24. This represents a 2.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders bought 22,200 shares of company stock worth $2,215,100 and sold 3,055 shares worth $353,097. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.